Referencias
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0.
- Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109-42.
- Brown RL. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol 2008; 35:298-308.
- Kloos RT. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005; 6:323-38.
- Lees W, Mansberg R, Roberts J, et al. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185MBq 131I. Eur J Nucl Med Mol Imaging 2002; 29:1421-7.
- Muratet JP, Daver A, Minier JF, et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1546-50.
- Vieras F. Preoperative scintigraphic detection of cervical metastases from thyroid carcinoma with technetium-99m pertechnetate. Clin Nucl Med 1985; 10:567-9.
- Khammash NF, Halkar RK, Abdel-Dayem HM. The use of technetium-99m pertechnetate in postoperative thyroid carcinoma. A comparative study with iodine-131. Clin Nucl Med 1988; 13:17-22.
- Kueh SS, Roach PJ, Schembri GP. Role of Tc-99m pertechnetate for remnant scintigraphy post thyroidectomy. Clin Nucl Med 2010; 35:671-4.
- Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiate thyroid cancer. Thyroid 2009; 19:1167-214.
- Sawka AM, Thephamongkhol K, Brouwers M, et al. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668-76.
- Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:457-80.
- Kim S, Wei JP, Braveman JM, et al. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004; 139:390-4.
- Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998; 133:419-25.
- Rodriguez E, Merlano S, Murguieitio R, et al. Terapia ablativa con yodo-131: juicio crítico de la evidencia. ¿Tiempo de cambiar paradigmas? Alasbimn Journal. Editorial, 20 octubre 2012.
- Schlumberger M, Catargi B, Borget I, et al. Strategies in radioiodine ablation in patients with low-risk thyroid cancer. N Eng J Med 2012; 366:1663-73.
- Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Eng J Med 2012; 366:1674-85.
- Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246:375-81.
- Sywak M, Cornford L, Roach P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006; 140:1000-7.
- Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 1998; 2:242-6.
- Hilditch TE, Dempsey MF, Bolster AA, et al. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 2002; 29:783-8.
- Giovanella L, Suriano S, Ricci R, et al. Postsurgical thyroid remnant estimation by 99mTc pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Head Neck 2011; 33:552-6.